| XLS |
|
|
Equity capital |
Reserves |
Gains/losses recognized immediately in equity |
|
|
| |||||
|
EUR million |
General |
Sub- |
Capital |
Retained |
Actuarial |
Avail- |
Derivative |
Exchange |
Equity |
Non- |
Equity |
|
Balance as of |
397.2 |
168.0 |
3,813.7 |
4,733.7 |
–228.7 |
18.8 |
47.5 |
509.9 |
9,460.1 |
53.5 |
9,513.6 |
|
Profit after tax |
– |
– |
– |
191.4 |
– |
– |
– |
– |
191.4 |
3.1 |
194.6 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
– |
–8.6 |
–21.2 |
376.7 |
346.9 |
4.9 |
351.8 |
|
Comprehensive income |
– |
– |
– |
191.4 |
– |
–8.6 |
–21.2 |
376.7 |
538.3 |
8.1 |
546.4 |
|
Dividend payments |
– |
– |
– |
– |
– |
– |
– |
– |
– |
–2.5 |
–2.5 |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–49.4 |
– |
– |
– |
– |
–49.4 |
– |
–49.4 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
0.2 |
–0.2 |
– |
– |
– |
– |
–0.3 |
–0.3 |
|
Balance as of |
397.2 |
168.0 |
3,813.7 |
4,875.9 |
–228.9 |
10.2 |
26.3 |
886.6 |
9,949.0 |
58.7 |
10,007.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of |
397.2 |
168.0 |
3,813.7 |
5,040.9 |
–370.4 |
–3.1 |
–61.1 |
1,344.6 |
10,329.8 |
42.0 |
10,371.8 |
|
Profit after tax |
– |
– |
– |
341.1 |
– |
– |
– |
– |
341.1 |
3.1 |
344.2 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
– |
21.6 |
13.3 |
–63.4 |
–28.5 |
–2.2 |
–30.7 |
|
Comprehensive income |
– |
– |
– |
341.1 |
– |
21.6 |
13.3 |
–63.4 |
312.6 |
0.9 |
313.5 |
|
Dividend payments |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–104.8 |
– |
– |
– |
– |
–104.8 |
– |
–104.8 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
–1.3 |
–0.1 |
– |
– |
– |
–1.4 |
0.1 |
–1.3 |
|
Balance as of |
397.2 |
168.0 |
3,813.7 |
5,275.9 |
–370.5 |
18.5 |
–47.8 |
1,281.2 |
10,536.1 |
43.0 |
10,579.1 |
